

## Exome Sequencing Identifies *PDE4D* Mutations as Another Cause of Acrodysostosis

Caroline Michot,<sup>1,10</sup> Carine Le Goff,<sup>1,10</sup> Alice Goldenberg,<sup>2</sup> Avinash Abhyankar,<sup>3</sup> Céline Klein,<sup>1</sup> Esther Kinning,<sup>4</sup> Anne-Marie Guerrot,<sup>2</sup> Philippe Flahaut,<sup>5</sup> Alice Duncombe,<sup>6</sup> Genevieve Baujat,<sup>1</sup> Stanislas Lyonnet,<sup>1</sup> Caroline Thalassinou,<sup>7</sup> Patrick Nitschke,<sup>8</sup> Jean-Laurent Casanova,<sup>3,9</sup> Martine Le Merrer,<sup>1</sup> Arnold Munnich,<sup>1</sup> and Valérie Cormier-Daire<sup>1,\*</sup>

Acrodysostosis is a rare autosomal-dominant condition characterized by facial dysostosis, severe brachydactyly with cone-shaped epiphyses, and short stature. Moderate intellectual disability and resistance to multiple hormones might also be present. Recently, a recurrent mutation (c.1102C>T [p.Arg368\*]) in *PRKARIA* has been identified in three individuals with acrodysostosis and resistance to multiple hormones. After studying ten unrelated acrodysostosis cases, we report here de novo *PRKARIA* mutations in five out of the ten individuals (we found c.1102C>T [p.Arg368\*] in four of the ten and c.1117T>C [p.Tyr373His] in one of the ten). We performed exome sequencing in two of the five remaining individuals and selected phosphodiesterase 4D (*PDE4D*) as a candidate gene. *PDE4D* encodes a class IV cyclic AMP (cAMP)-specific phosphodiesterase that regulates cAMP concentration. Exome analysis detected heterozygous *PDE4D* mutations (c.673C>A [p.Pro225Thr] and c.677T>C [p.Phe226Ser]) in these two individuals. Screening of *PDE4D* identified heterozygous mutations (c.568T>G [p.Ser190Ala] and c.1759A>C [p.Thr587Pro]) in two additional acrodysostosis cases. These mutations occurred de novo in all four cases. The four individuals with *PDE4D* mutations shared common clinical features, namely characteristic midface and nasal hypoplasia and moderate intellectual disability. Metabolic screening was normal in three of these four individuals. However, resistance to parathyroid hormone and thyrotropin was consistently observed in the five cases with *PRKARIA* mutations. Finally, our study further supports the key role of the cAMP signaling pathway in skeletogenesis.

Acrodysostosis (MIM 101800) is a dominantly inherited condition consisting of (1) skeletal dysplasia characterized by facial dysostosis with nasal hypoplasia (a depressed nasal bridge and prominent mandible), severe brachydactyly with short broad metatarsals, metacarpals, and phalanges, cone-shaped epiphyses, advanced bone maturation, spinal stenosis, and short stature; (2) resistance to multiple hormones, including parathyroid hormone and thyrotropin; and (3) possible neurological involvement (moderate to mild intellectual disability).<sup>1,2</sup> Differential diagnoses include Albright hereditary osteodystrophy (MIM 103580) and pseudopseudohypoparathyroidism (MIM 612463), which are both due to loss-of-function mutations in *GNAS* ( $\alpha$ -stimulatory subunit of the G protein) (MIM 139320) and are characterized by less severe hand and foot involvement.<sup>3</sup>

A recurrent c.1102C>T mutation in *PRKARIA* (MIM 188830) has been recently identified in three cases of acrodysostosis with resistance to multiple hormones.<sup>4</sup> This gene encodes the cyclic AMP (cAMP)-dependent regulatory subunit of protein kinase A. The mutated subunit impairs the protein-kinase-A response to cAMP and accounts for hormone resistance and skeletal abnormali-

ties resembling those observed in Albright hereditary osteodystrophy.

After studying ten unrelated individuals with acrodysostosis, we found *PRKARIA* mutations in five out of the ten, and we show that most of the remaining cases were accounted for by mutations in phosphodiesterase, 4D (*PDE4D* [MIM 600129]), which is also involved in cAMP metabolism.

Ten unrelated cases were included in this study. There was no family history, and each individual was the only affected member in his family. Inclusion criteria were the following: (1) the presence of severe generalized brachydactyly affecting metacarpals and phalanges and associated with cone-shaped epiphyses and (2) the exclusion of Albright hereditary osteodystrophy on the basis of normal bioactivity of the Gs alpha subunit and normal *GNAS* sequencing.

We performed a complete screening of phosphocalcic metabolism and blood levels of creatinine, calcium, phosphorus, thyroxin, thyrotropin, 25-hydroxyvitaminD, 1,25-dihydroxyvitaminD, parathyroid hormone (PTH), and fibroblast growth factor 23, as well as urinary levels of creatinine, calcium, and phosphorus. The clinical

<sup>1</sup>Unité Institut National de la Santé et de la Recherche Médicale U781, Département de Génétique, Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker Enfants Malades, Paris 75015, France; <sup>2</sup>Service de Génétique Médicale, Centre Hospitalier Universitaire-Hôpitaux de Rouen, Rouen 76100, France; <sup>3</sup>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA; <sup>4</sup>The Ferguson-Smith Centre for Clinical Genetics, Royal Hospital for Sick Children-Yorkhill, Dalnair Street, Glasgow G3 8SJ, Scotland; <sup>5</sup>Service de Pédiatrie, Centre Hospitalier Universitaire-Hôpitaux de Rouen, Rouen 76100, France; <sup>6</sup>Service d'Ophtalmologie, Centre Hospitalier Universitaire-Hôpitaux de Rouen, Rouen 76100, France; <sup>7</sup>Endocrinologie Gynécologie Diabétologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Paris 75015, France; <sup>8</sup>Plateforme de Bioinformatique, Université Paris Descartes, Paris 75015, France; <sup>9</sup>Unité Institut National de la Santé et de la Recherche Médicale U980, Laboratory of Human Genetics of Infectious Diseases, Necker Medical School, University Paris Descartes, Paris 75015, France

<sup>10</sup>These authors contributed equally to this work

\*Correspondence: [valerie.cormier-daيرة@inserm.fr](mailto:valerie.cormier-daيرة@inserm.fr)

DOI 10.1016/j.ajhg.2012.03.003. ©2012 by The American Society of Human Genetics. All rights reserved.

radiological and biochemical details are summarized in Table 1 and Figure 1.

Informed consent for participation, sample collection, and photograph publication was obtained via protocols approved by the Necker Hospital ethics committee.

We sequenced *PRKARIA* (RefSeq accession number NM\_002734.3) by using specific primers (available upon request) in the ten individuals. De novo *PRKARIA* mutations, including the recurrent mutation,<sup>4</sup> were identified in five out of the ten individuals (c.1102C>T [p.Arg368\*] was found in four of the five, and c.1117T>C [p.Tyr373His] was found in one of the five) (Table 1). This missense mutation was predicted to be damaging by PolyPhen, was found to alter a conserved amino acid located in the catalytic domain, and was not identified in alleles from 200 ethnically matched controls.

The exclusion of *PRKARIA* in five acrodysostosis cases prompted us to perform exome sequencing in two of these five individuals. Exome capture was performed with the SureSelect Human All Exon kit (Agilent Technologies).<sup>5</sup> Single-end sequencing was performed on an Illumina Genome Analyzer Iix (Illumina) and generated 72 bp reads. For sequence alignment, variant calling, and annotation, we aligned the sequences to the human genome reference sequence (hg18 build) by using the Burrows-Wheeler Aligner.<sup>6</sup> Downstream processing was carried out with the Genome Analysis Toolkit (GATK<sup>7</sup>), SAMtools,<sup>8</sup> and Picard tools. Substitution calls were made with GATK Unified Genotyper, whereas indel calls were made with a GATK IndelGenotyperV2. All calls with a read coverage  $\leq 2\times$  and a Phred-scaled SNP quality of  $\leq 20$  were filtered out. All the variants were annotated with an in-house -developed annotation software system. We first focused our analyses on nonsynonymous variants, splice-acceptor and donor-site mutations, and coding indels because we anticipated that synonymous variants would be far less likely to cause disease (Table S1, available online). We also defined variants as previously unidentified if they were absent from control populations and from all datasets, including dbSNP129, the 1000 Genomes Project, and in-house exome data.

On the basis of the dominant mode of inheritance of acrodysostosis, we selected eight candidate genes that all harbor heterozygous mutations (Table S2). Given the involvement of *PRKARIA*, a cAMP-activated protein kinase A, in some acrodysostosis cases,<sup>4</sup> we then only considered gene(s) that encode proteins involved in the cAMP signaling pathway. Therefore, we regarded *PDE4D* (RefSeq accession number NM\_001104631) as the best candidate gene. Indeed, *PDE4D* encodes a class IV cAMP-specific phosphodiesterase that regulates cAMP concentration. Exome analysis detected two *PDE4D* mutations (c.673C>A [p.Pro225Thr] and c.677T>C [p.Phe226Ser]) in the two individuals. These results were confirmed by Sanger sequencing. Subsequent screening of the 15 *PDE4D* coding exons in the three remaining cases led to the identification of two distinct heterozygous missense mutations

(c.568T>G [p.Ser190Ala] and c.1759A>C [p.Thr587Pro]) in two additional cases. These mutations were not observed in the parents of acrodysostosis-affected individuals, confirming that they occurred de novo.

We identified a total of four distinct heterozygous *PDE4D* mutations in four individuals (Table 1). Among them, the p.Ser190Ala substitution affected a serine residue predicted to be phosphorylated (Uniprot database), and the p.Thr587Pro substitution disturbed the conserved catalytic PDEase\_I domain (pfam database), which confers the 3'/5'-cyclic nucleotide phosphodiesterase activity. The two remaining alterations (p.Pro225Thr and p.Phe226Ser) affected conserved residues across species. All four mutations were considered to be pathogenic by PolyPhen and were absent from alleles in 200 ethnically matched controls.

Here, we report *PDE4D* mutations in four unrelated cases of acrodysostosis and *PRKARIA* mutations in five cases. All mutations occurred de novo, providing further evidence that acrodysostosis has a dominant mode of inheritance.

After we divided up the acrodysostosis-affected individuals and grouped them according to the mutations they had, our study revealed interesting genotype-phenotype correlations. Indeed, the four individuals with *PDE4D* mutations shared characteristic facial features, namely midface hypoplasia with the canonical nasal hypoplasia initially reported in acrodysostosis and moderate intellectual disability with speech delay.<sup>1,2</sup> The characteristic facial dysostosis and intellectual disability were neither observed in our individuals with *PRKARIA* mutations nor mentioned in the three previously reported cases.<sup>4</sup> Along the same lines, hormone resistance was observed in only one person with *PDE4D* mutations—case 6 had increased PTH levels and normal serum-phosphate levels—whereas hormone resistance was consistently observed in individuals carrying *PRKARIA* mutations (all five suffered from chronic resistance to parathyroid hormone, and four of the five had peripheral hypothyroidism). Although our study does not allow generalized conclusions, our findings might suggest that individuals with facial dysostosis and moderate intellectual disability should be screened for *PDE4D* mutations, whereas individuals with less characteristic facial features, no intellectual disability, and hormone resistance should be screened for mutations in *PRKARIA*.

The five individuals harboring *PRKARIA* mutations presented with growth retardation ( $< -2$  standard deviations [SDs]) and decreased growth speed in late childhood (between 7 and 13 years of age). The adult individuals had a final height  $< -3$  SDs. Alternatively, the cases harboring *PDE4D* mutations presently have normal growth charts, but they are only 3–7 years old, and predicting final adult height is therefore impossible. It is worth noting that two out of the four *PDE4D* cases presented with an acute intracranial hypertension due to sinus thrombosis; both of these individuals required derivation

**Table 1. Clinical, Radiological, and Biochemical Data of the Ten Acrolystosis Individuals Reported**

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
Sex	female	male	female	female	female	male	male	male	male	female
<i>PRKARIA</i> mutation	c.1102C>T	c.1102C>T	c.1102C>T	c.1117T>C	c.1102C>T	–	–	–	–	–
<i>PDE4D</i> mutation	–	–	–	–	–	c.673C>A	c.677T>C	c.568T>G	c.1759A>C	–
IUGR	no	no	no	yes	no	yes	no	no	no	no
Postnatal growth retardation (<–2 SDs)	yes (26 years old)	no (8 years old)	yes (13 years old)	yes (22 years old)	yes (34 years old)	no (7 years old)	no (4 years old)	no (4 years old)	no (3 years old)	yes (38 years old)
Advanced bone age	–	yes	yes	–	–	yes	yes	yes	yes	–
<b>Facial dysostosis</b>										
Nasal hypoplasia	no	no	no	no	no	yes	yes	yes	yes	no
Depressed nasal bridge	no	no	yes	no	yes	yes	yes	yes	yes	no
Prominent mandible	no	no	no	no	yes	no	no	yes	no	yes
<b>Peripheral dysostosis</b>										
Severe brachydactyly	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Short metatarsals, metacarpals, and phalanges	yes	yes	yes	yes	yes	yes	yes	yes	yes	yes
Cone-shaped epiphyses	yes (childhood)	yes	yes	yes (childhood)	yes (childhood)	yes	yes	yes	yes	nd
<b>Hormonal screening</b>										
PTH (n = 10–46 ng/l)	95	79	116	84	142	76	39	24	19	normal
Calcemia (n = 2.2–2.7 mmol/l)	2.35	2.47	2.4	2.57	2.37	2.18	2.47	2.4	2.5	2.38
Phosphoremia (n = 1.3–1.85 mmol/l)	1.23	1.56	1.76	nd	1.3	1.54	1.68	1.81	1.7	1.8
25-OHvitD (n = 30–80 ng/ml)	nd	26	16	nd	22	26	25	45	30	nd
1,25-diOHvitD (pg/ml)	nd	39		106		65	53	nd	nd	nd
FGF23 (n = 1–120 UI/ml)	nd	nd	nd	nd	145	90	112	171.2	60.9	nd
Free T4 (n = 7.5–15 pmol/l)	8.65	hypothyroidism	hypothyroidism	hypothyroidism	16.71 treatment	10.4	10	14.3	17	17
TSH (n = 0.34–5.6 mUI/l)	2.67	13.41	15.42	increased	0.16	2.59	2.51	3.58	2.77	1.81
Calciuria (n = 1.5–6 mmol/l)	nd	<0.2	nd	nd	nd	0.86	1.28	1.44	2.27	nd

**Table 1. Continued**

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
Phosphaturia (n = 10–50 mmol/l)	nd	14.8	nd	nd	nd	13.76	7.12	36.7	4.70	nd
Creatininuria (mmol/l)	nd	4.5	nd	nd	nd	6.3	2.08	11.7	4.15	nd
<b>Neurology</b>										
Intellectual disability	no	no	no	no	no	yes; speech delay requiring orthophony; fine-motor-skill impairment	yes; speech delay requiring orthophony; fine-motor-skill impairment	yes; speech delay; psychomotor delay (walked at 17 months of age)	yes; speech delay; psychomotor delay requiring physiotherapy	no
Other			spinal stenosis; carpal tunnel			intracranial hypertension with jugular stenosis requiring derivation		intracranial hypertension with thrombophlebitis of the transverse sinus and jugular (treated by acetazolamide, anticoagulant, and derivation)		spinal stenosis

The following abbreviations are used: IUGR, intrauterine growth retardation; SDs, standard deviations; nd, not done; PTH, parathyroid hormone; 25-OHvitD, 25-hydroxyvitaminD; 1,25-diOHvitD, 1,25-dihydroxyvitaminD; FGF23, fibroblast growth factor 23; T4, thyroxin; and TSH, thyrotropin.


surgery and medical treatment. This observation should prompt the careful investigation of headache complaints in such cases. This feature, hitherto unreported in *PRKARIA*-mutation-positive individuals, might be another distinctive characteristic specific to the clinical spectrum of symptoms associated with *PDE4D* mutations. Finally, neither *PDE4D* nor *PRKARIA* mutations were found in one adult individual who had characteristic skeletal features but no hormone resistance or facial dysostosis. One cannot exclude a molecular defect not detectable by Sanger sequencing, but it is also conceivable that other genes might account for acrodysostosis.

Considering *PRKARIA* mutations, we confirm that c.1102C>T is a recurrent mutation observed in seven of the eight patients reported so far, whereas only one missense mutation that changes a conserved amino acid located in the cAMP binding domain has been identified. Interestingly, the Arg388\* substitution is considered a gain-of-function mutation because it decreases protein-kinase-A sensitivity to cAMP.<sup>4</sup> In contrast, germ-line loss-of-function mutations resulting in constitutive activation of protein kinase A are responsible for Carney complex (MIM 160980), an autosomal-dominant multiple-neoplasia syndrome characterized by cardiac, endocrine, cutaneous, and neural myxomatous tumors and pigmented lesions of the skin and mucosae.<sup>9</sup>

All mutations that we have identified in *PDE4D* are heterozygous missense mutations and are presumably responsible for impaired phosphodiesterase activity. *PDE4D* belongs to the cAMP-hydrolyzing phosphodiesterase family, which is directly involved in the rate of cAMP degradation. Considering the crucial role of cAMP in intracellular signaling in response to a number of membrane-impermeable hormones, a dysregulation of cAMP levels could be the underlying mechanism of the acrodysostosis that results from *PDE4D* mutations.

The cAMP-specific PDE4 family is widely expressed, and *PDE4* isoforms have similar catalytic functions, but they have distinct cellular functions because of differences in specific intracellular trafficking and signaling-complex formation.<sup>10,11</sup> *PDE4D* uses different promoters to generate multiple alternatively spliced transcript variants (at least nine) that encode functional proteins; this might explain the phenotype variability observed in the four reported cases.

Of note, mice deficient in *PDE4D* exhibited delayed growth and female infertility due to impaired ovulation;<sup>12</sup> these two symptoms have also been described in acrodysostosis cases.<sup>13</sup> Mouse models have also revealed that *PDE4D* plays a critical role in the memory and hippocampal neurogenesis mediated by cAMP signaling.<sup>14</sup> Flies deficient in the *PDE4D* homolog, *dunce*, also display impaired central-nervous-system and reproductive function.<sup>15</sup> All together, these data support the involvement of *PDE4D* impairment in the regulation of cAMP signaling, especially in growth and central-nervous-system development.



**Figure 1. Pictures and X-Rays of Individuals 6 and 8 with *PDE4D* Mutations**

(A1 and B1) Full-face pictures of individuals 6 (A) and 8 (B) showing facial dysostosis with a flat nasal bridge and nasal hypoplasia.

(A2 and B2) Profile pictures show malar hypoplasia.

(A3) Palmar face of right hand.

(A4 and B3) Dorsal face of hands, which are broad and shortened.

(A5 and B4) Standard X-rays of both hands show severe brachydactyly with short, broad metacarpals and phalanges, cone-shaped epiphyses (arrows), and advanced carpal maturation.

Finally, our findings further support the key role of the cAMP signaling pathway in skeletogenesis, as previously shown for Albright hereditary osteodystrophy due to *GNAS* mutations. Ongoing studies will highlight the specific link between *PRKAR1A* and *PDE4D*, which are both involved in cAMP signaling and responsible for acrodysostosis.

### Supplemental Data

Supplemental Data include two tables and can be found with this article online at <http://www.cell.com/AJHG>.

### Acknowledgments

We thank all individuals and their families for their contribution to this work.

Received: December 9, 2011

Revised: January 11, 2012

Accepted: March 6, 2012

Published online: March 29, 2012

### Web Resources

The URLs for data presented herein are as follows:

Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org>

Pfam, <http://www.sanger.ac.uk/resources/databases/pfam.html>

Picard Tools, <http://picard.sourceforge.net>

Polyphen, <http://genetics.bwh.harvard.edu/pph/>

Uniprot, <http://www.uniprot.org/>

### References

- Maroteaux, P., and Malamut, G. (1968). Acrodysostosis. *Presse Med.* 76, 2189–2192.
- Robinow, M., Pfeiffer, R.A., Gorlin, R.J., McKusick, V.A., Renuart, A.W., Johnson, G.F., and Summitt, R.L. (1971). Acrodysostosis. A syndrome of peripheral dysostosis, nasal hypoplasia, and mental retardation. *Am. J. Dis. Child.* 121, 195–203.
- Bastepe, M., and Jüppner, H. (2005). *GNAS* locus and pseudo-hypoparathyroidism. *Horm. Res.* 63, 65–74.
- Linglart, A., Menguy, C., Couvineau, A., Auzan, C., Gunes, Y., Cancel, M., Motte, E., Pinto, G., Chanson, P., Bougnères, P., et al. (2011). Recurrent *PRKAR1A* mutation in acrodysostosis with hormone resistance. *N. Engl. J. Med.* 364, 2218–2226.
- Byun, M., Abhyankar, A., Lelarge, V., Plancoulaine, S., Palanduz, A., Telhan, L., Boisson, B., Picard, C., Dewell, S., Zhao, C., et al. (2010). Whole-exome sequencing-based discovery of *STIM1* deficiency in a child with fatal classic Kaposi sarcoma. *J. Exp. Med.* 207, 2307–2312.
- Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–1760.
- McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernysky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 20, 1297–1303.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup. (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079.
- Kirschner, L.S., Carney, J.A., Pack, S.D., Taymans, S.E., Giatzakis, C., Cho, Y.S., Cho-Chung, Y.S., and Stratakis, C.A. (2000). Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. *Nat. Genet.* 26, 89–92.
- Rall, T.W., and Sutherland, E.W. (1958). Formation of a cyclic adenine ribonucleotide by tissue particles. *J. Biol. Chem.* 232, 1065–1076.

11. Sutherland, E.W., and Rall, T.W. (1958). Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. *J. Biol. Chem.* *232*, 1077–1091.
12. Jin, S.L., Richard, F.J., Kuo, W.P., D'Ercole, A.J., and Conti, M. (1999). Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. *Proc. Natl. Acad. Sci. USA* *96*, 11998–12003.
13. Graham, J.M., Jr., Krakow, D., Tolo, V.T., Smith, A.K., and Lachman, R.S. (2001). Radiographic findings and Gs-alpha bioactivity studies and mutation screening in acrodysostosis indicate a different etiology from pseudohypoparathyroidism. *Pediatr. Radiol.* *31*, 2–9.
14. Li, Y.F., Cheng, Y.F., Huang, Y., Conti, M., Wilson, S.P., O'Donnell, J.M., and Zhang, H.T. (2011). Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. *J. Neurosci.* *31*, 172–183.
15. Dudai, Y., Jan, Y.N., Byers, D., Quinn, W.G., and Benzer, S. (1976). *dunce*, a mutant of *Drosophila* deficient in learning. *Proc. Natl. Acad. Sci. USA* *73*, 1684–1688.